Portfolio News

MediLink’s YL217 received FDA Clearance of IND Application

MicroPort® CardioFlow’s VitaFlow Liberty® Obtains Marketing Approval in India

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

MediLink’s YL217 received FDA Clearance of IND Application

TriApex Launches Its New U.S. Laboratories in Philadelphia

Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe

Junshi Biosciences Announces Toripalimab’s Approval in Australia

JPM 2025 | RemeGen: Maximize Commercial Potential of Pipelines Through Indication Expansion and Therapy Innovation

Argo Biopharma to Present at the J.P. Morgan 43rd Annual Healthcare Conference

CirCode Biomed Just Received First Ever Circular RNA IND Approval from NMPA

MediLink Therapeutics Announces Strategic Partnership with Zai Lab to Develop a Novel LRRC15 Antibody-Drug Conjugate

MicroPort EverPace Introduces Genesis RMN™ Magnetic Navigation Robot to China, Redefining Traditional Ablation Techniques

VitaFlow Liberty® Flex Transcatheter Aortic Valve Implantation System Receives Market Approval from NMPA

The 10th clinical product! Evopoint announces that the PARG inhibitor XNW29016 has obtained the CTA approval and will initiate a Phase I clinical trial in China in the near future

MediLink Announces YL201 Granted Orphan-Drug Designation by the US FDA

Evopoint has submitted the Pre-NDA application for its novel drug Funobactam (XNW4107), offering new hope for HABP/VABP patients

SinoMab Completed Patient Enrollment in Phase 1b Clinical Trial

Qi Biodesign Completes $75 Million in Total Funding to Drive Genome Editing Innovations

Evopoint Biosciences and Everest Medicines Collaboration Advances with Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor XNW1011

Evopoint and Everest Medicines announce progress in partnership: positive interim data from phase 1b/2a clinical study of novel BTK inhibitor XNW1011

MicroPort®’s Two Products Approved for Fast-Track Registration as Innovative Medical Device in China

Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab

Biolink Secures Hundreds of Millions RMB New Financing to Fuel Innovations in Bioprocessing “Made in China”

BLA Accepted and Priority Review Granted to Disitamab Vedotin for Its Third Indication of HER2-Positive Advanced Breast Cancer with Liver Metastasis

Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline

Junshi Biosciences Announces Ongericimab’s NDA Approval in China

MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy

Akeso’s Ebronucimab（PCSK9) Approved for Two Indications for the Treatment of Hypercholesterolemia in China

MediLink Therapeutics Wins the 2024 Endpoints 11 Award

HM2002 Injection Completes First Patient Dosing Circular RNA Drug Officially Enters Clinical Trial Stage

Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab

Evopoint’s EZH2 inhibitor XNW5004 Achieves Breakthrough Therapy Designation

Qi-biodesign and MGI have reached a strategic cooperation

CirCode Biomed Launches First-in-Human Trial of Circular RNA at Ruijin Hospital

Enrollment Completed in Phase 3 Clinical Study of Disitamab Vedotin Combined with PD-1 Inhibitor as First-Line Treatment for Advanced Urothelial Carcinoma

First Patient In Achieved in the Global Multicenter Phase III Trial on Telitacicept for Myasthenia Gravis 05

Bellen is awarded a Bronze medal from EcoVadis

Argo Biopharma Announces Completion of First Participant Dosing in China Phase I Clinical Study of BW-03, a Novel RNAi Therapeutics for the Treatment of CHB

FDA Grants Fast-Track Designation Status for Evopoint New-Generation ADC Drug XNW27011

Qi-biodesign's high oleic acid soybeans have been granted an exemption by the USDA

MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech

MicroPort® CardioFlow Receives Approval for VitaFlow Liberty® in the EU

First Patient Dosed in Phase 2 Clinical Trial of Argo Biopharma BW-01, a Novel siRNA Drug for the Treatment of Severe Hypertriglyceridemia

BioLink Formally Announces Its India Office Now Is Fully Functional And Operational

Qi-biodesign and G&P Agritech have signed a strategic cooperation agreement

Qi-biodesign has initiated a strategic partnership with Triumph Haofeng

RemeGen's Telitacicept Granted Fast Track Designation by US FDA for Treatment of Primary Sjögren's Syndrome Following Permission of the Phase 3 Multicenter Global Clinical Trial

Johnson & Johnson Completes Acquisition of Ambrx

iF Design Winner: BioHub® DS Single-Use Desktop Mixing System

CirCode Announces Feasibility Study Agreement to Explore the Potential of Circular RNA Therapeutics

The "Top 10 Scientific Advances of 2023, China" have been announced

BioLink Successfully Completes Series A+ Strategic Financing, Continues to Empower China's Bioprocessing with Innovation

Evopoint Completes RMB 700 Million Series E Financing to Accelerate R&D and Commercialization of Innovative Drugs

Evopoint's New Gout Drug XNW3009 Enrolled the First Patient in its Phase III Clinical Trial

MicroPort EverPace Receives CE MDR Certification for Its Latest Generation Columbus™ 3D EP Navigation System

MicroPort® CardioFlow Receives Approval for Its AnchorMan® LAAC System in China

Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority

Argo Biopharma has completed phase 1 clinical trials for BW-01, a siRNA candidate for cardiovascular diseases, in China and Australia.

JPM Healthcare Conference 2024|Dr. Fang Jianmin’s Speech: Promote the Global Development of Telitacicept at Full Speed and Create a Pioneer Blockbuster Drug in the Field of B Cell-mediated Autoimmunity

BioLink and Verdot Forge Strategic Partnership to Advance Bioprocessing Technologies in China

Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis.

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation ADC in Oncology

MediLink Therapeutics Announces Latest Business Progress with Nona Biosciences

Continuously Ranked | BioLink Named One of China's Top 100 Life Science Service Brands

SinoMab Awarded the "Best Small and Medium-Cap Company” in the “8th Zhitong Caijing Listed Company Awards” Development Potential Recognised by The Capital Market

Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA

MicroPort® CardioFlow Finishes VitaFlow Liberty® Pre-Market Implantations

Argo Biopharma closed series A+ financing of over 40 milion US dollars led by CS Capital.

Junshi Biosciences Announces FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech

MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech

MicroPort EP Receives FireMagic™ TrueForce™ Ablation Catheter Approval

MediLink Therapeutics is studying YL202 in advanced lung and breast cancer patients.

MediLink Therapeutics is studying YL202 in advanced lung and breast cancer patients.

CirCode Biomed Closes Multi-Million-Dollar Series A Financing

Argo Biopharma’s first siRNA drug approved for clinical study in China, the United States, and Australia.

CirCode Announces Research Agreement with Pfizer to Explore the Potential of Circular RNA Therapeuti

Bellen has successfully obtained a Drug production license

Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer

Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer

Junshi Biosciences Announces Collaboration with Dr. Reddy’s to Develop and Commercialize Toripalimab in 21 Countries

SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis

Evopoint Announces Clinical Trial Collaboration Agreement with MSD for the Study of XNW5004 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors

MicroPort EP FDA Approved for EasyFinder™ Fixed Curve Diagnostic Catheter